This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Go To Market Consulting Inc. And Debiopharm Group Collaborate To Identify Early Stage In-licensing Opportunities On The US West Coast

LAUSANNE, Switzerland and SAN FRANCISCO, September 5, 2013 /PRNewswire/ --

Go To Market Consulting Inc. (Go To Market), a San Francisco headquartered business development representation and marketing services life sciences consulting firm, and Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, have entered into an alliance to identify and scout West Coast companies, research institutes and/or individual investigators with in-licensing opportunities, including new compounds, products and/or technologies in oncology, auto-immune, infectious disease and metabolic conditions. Go To Market will collaborate with Debiopharm's existing in-house scouting team for first in-class opportunities for small molecule, antibody and peptide based product candidates.

In recognition of the depth and breadth of life science innovation in the West and in particular, the San Francisco Bay area, known for its culture of innovation, Debiopharm has selected Go To Market to strengthen its local activity in the region. Go To Market will work with Debiopharm's experienced scouting team to further increase the company's accessibility to in-licensing opportunities. David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: "We have selected Go To Market because of their strength and understanding in the life sciences product development area. Their successful presence on the West Coast is a major asset to our search for new molecules. With this partnership we are deepening our commitment to finding the most promising drugs to develop for patients."

Maria Chiam, Founder of Go To Market added: "the West Coast is a rich area in science innovation. Debiopharm's track record of investing into and collaborating with early stage biopharmaceutical programs make it a choice partner for researchers and organizations wanting to move their preclinical programs into clinical development. Go To Market Consulting is delighted to work with Debiopharm to bring next generation therapeutics and diagnostic and personalized medicine initiatives to the market."

About Go To Market Consulting Inc.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs